Anika Therapeutics reported $14.8M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbott ABT:US $ 4933M 54M
Acorda Therapeutics ACOR:US $ 8.8M 2.83M
Agenus AGEN:US $ 2.02M 1.48M
Agios Pharmaceuticals AGIO:US $ 0.44M 0.1M
Anika Therapeutics ANIK:US $ 14.8M 0.09M
ChemoCentryx CCXI:US 803K 598K
Clovis Oncology CLVS:US $ 9.22M 0.2M
Halozyme Therapeutics HALO:US $ 33.94M 18.02M
Heron Therapeutics HRTX:US $ 16.18M 4.82M
Insmed INSM:US $ 16.4M 4.2M
Integra Lifesciences IART:US $ 143.27M 5.23M
Intrexon XON:US $ 1.81M 15.29M
Johnson & Johnson JNJ:US $ 7919M 321M
Karyopharm Therapeutics KPTI:US $ 939K 487K
Ligand Pharmaceuticals LGND:US $ 12.36M 7.66M
MacroGenics MGNX:US 2.4M 2.35M
Merit Medical Systems MMSI:US $ 159.91M 5.4M
Peregrine Pharmaceuticals PPHM:US $ 27.58M 3.33M
Rigel Pharmaceuticals RIGL:US $ 1.04M 0.92M
Stryker SYK:US $ 1650M 102M
Surmodics SRDX:US $ 5.14M 0.03M
Veracyte VCYT:US $ 25.03M 1.32M
Zimmer Biomet Holdings Inc ZBH:US $ 511M 11M